CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma

CD19-directed chimeric antigen receptor (CD19CAR) T-cell therapy has been successful in treating several B-cell lineage malignancies, including B-cell non-Hodgkin lymphoma (NHL). This modality has not yet been extended to NHL manifesting in the central nervous system (CNS), primarily as a result of...

Descripción completa

Detalles Bibliográficos
Autores principales: Siddiqi, Tanya, Wang, Xiuli, Blanchard, M. Suzette, Wagner, Jamie R., Popplewell, Leslie L., Budde, L. Elizabeth, Stiller, Tracey L., Clark, Mary C., Lim, Laura, Vyas, Vibhuti, Brown, Christine E., Forman, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945630/
https://www.ncbi.nlm.nih.gov/pubmed/34492703
http://dx.doi.org/10.1182/bloodadvances.2020004106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945630/
https://www.ncbi.nlm.nih.gov/pubmed/34492703
http://dx.doi.org/10.1182/bloodadvances.2020004106

Ejemplares similares